Success Stories: With Premium Processing and the Efforts of Our Teammates, A Professor in the Field of Pharmaceutical Biotechnology Secures EB1-A Approval in Just 1 Month, and 4 Days.

Posted by wegreened on May 19, 2024 in EB1 Green Card, Pharmaceutical Biotechnology

Client’s Testimonial:

“I would like to thank the law firm for all this help. Your service is highly appreciated”

On September 12^th, 2023, we received another EB-1A (Alien of Extraordinary Ability) approval for a Professor in the field of Pharmaceutical Biotechnology (Approval Notice).

General Field: Pharmaceutical Biotechnology

Position at the Time of Case Filing: Professor

Approval Notice Date: September 12^th, 2023

Processing Time: 1 month, 4 days (Premium Processing Requested)

Case Summary:

Having accumulated two recommendation letters, our client, a professor, working in the field of pharmaceutical biotechnology after completing his Ph.D. degree in biochemistry, approached us to file his alien of extraordinary ability (EB1-A) petition.

Since a petition for the first preference category of individuals with extraordinary ability, (“EB1- A”), unlike the employment-based immigration visa under the second preference (“EB-2”), at least requires:

Evidence of original contributions, usually through publication, is of major significance in the foreign national’s science, academic, artistic, or athletic field.
No specific job offer/labor certification is required for a foreign person as long as he/she is entering the United States to continue work in the field where he/she has an extraordinary ability; therefore, self-petition is allowed.
Performance in a significant role for organizations or establishments that have a distinguished reputation.
Receipt of a higher salary or remuneration than is usual in the field.
Other comparable evidence if the above evidence does not readily apply to the foreign national’s occupation.

Therefore, we assimilated the following essentials from his academic and professional records in his petition packet to make a convincing case in his favor:

His research addresses some of our nation’s and the world’s most pressing issues, including the need for the development of effective antibiotics, and antiviral agents particularly in developing COVID-19 treatments and addressing drug resistance.
He is particularly well-known for his contributions to identifying secondary metabolites from natural products for COVID-19 treatments.
His research has resulted over 60 peer-reviewed scientific articles, being cited 1,396 times from several countries according to Google Scholar.
He has conducted 100 reviews to date.
His study has also received funding from many government/ private organizations which supports projects that provide knowledge and technology for national socioeconomic development.

After evaluating our client’s research, we deduced that it stands out in the field due to its applications in identifying drug candidates for the treatment of COVID-19 and advancing further research in pharmaceutical biotechnology. His work is dedicated to advances in pharmaceutical biotechnology, which are matters of critical national importance. Researchers who are highly skilled in this area are thus crucial to the United States.

Finally, he achieved his EB1-A (Alien of Extraordinary Ability) approval in 1 month and 4 days only (thanks to premium processing).

We are delighted to be part of his victorious journey and would like to send him best wishes for his future endeavors.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Sixty-four Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With nearly 64,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Tens of Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to nearly 64,000 in 2025.

Track Record of Success EB-1 and NIW Approvals

(2012.01 - 2025.12)

Category	Approval or Refund^®		Approval or Refiling^TM
	Approval or Refund^®
Category	Approved Sum	Success Rate	Approved Sum	Success Rate
NIW	42,047	99%	5,258	97%
EB1A	9,218	91%	4,534	86%
EB1B	1,488	98%	448	93%
Total	52,753	98%	10,240	92%